Differing decisions on prostate cancer therapies between the UK’s National Institute for Health and Clinical Excellence and Germany’s Institute for Quality and Efficiency in Healthcare highlight the different evidence base between the two health technology assessment authorities – but that could all change later this year when IQWiG expands its assessments to consider cost.
NICE is not likely to recommend Janssen Inc.’s Zytiga for castrate-resistant metastatic prostate cancer because it is too expensive...